347331-78-6

Basic information

• Product Name: 1-(4-BROMO-PHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBALDEHYDE
• Synonyms: 1-(4-bromophenyl)-2,5-dimethylpyrrole-3-carbaldehyde
• CAS NO: 347331-78-6
• Molecular Formula: C₁₃H₁₂BrNO
• Molecular Weight: 278.16
• Mol File: 347331-78-6.mol

Chemical Properties

• Melting Point: 117-119°
• Boiling Point: 382.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -6.13±0.70(Predicted)
• CAS DataBase Reference: 1-(4-BROMO-PHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BROMO-PHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBALDEHYDE(347331-78-6)
• EPA Substance Registry System: 1-(4-BROMO-PHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBALDEHYDE(347331-78-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 347331-78-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(4-BROMO-PHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBALDEHYDE is used as a building block in organic synthesis for the creation of various biologically active molecules. Its presence in the synthesis process is crucial due to its ability to form complex molecular structures that can exhibit a range of biological activities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(4-BROMO-PHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBALDEHYDE is utilized as a key intermediate in the development of new drugs. Its unique properties allow researchers to explore its potential in treating various diseases and conditions, making it a valuable asset in medicinal chemistry.
Used in the Synthesis of Biologically Active Molecules:
1-(4-BROMO-PHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBALDEHYDE is employed as a precursor in the synthesis of biologically active molecules. Its reactivity and structural features enable the production of compounds that can interact with biological targets, offering potential applications in therapeutic interventions.
Overall, 1-(4-BROMO-PHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBALDEHYDE's versatility in different applications across various industries highlights its importance in the fields of chemistry and medicine. Its role in the synthesis of new compounds and its potential in pharmaceutical research make it a compound of significant interest for scientists and researchers alike.

Upstream product

• 106-40-1 4-bromo-aniline 
• 5044-24-6 1-(4-Bromo-phenyl)-2,5-dimethyl-1H-pyrrole 
• 68-12-2 N,N-dimethyl-formamide 
• 110-13-4 2,5-hexanedione 

Downstream Products

• 1428183-51-0 C₂₁H₂₁BrN₂O₃ 

Relevant articles and documents

Synthesis, structure and in vitro anti-trypanosomal activity of non-toxic arylpyrrole-based chalcone derivatives

With an intention of identifying chalcone derivatives exhibiting anti-protozoal activity, a cohort of relatively unexplored arylpyrrole-based chalcone derivatives were synthesized in moderate to good yields. The resultant compounds were evaluated in vitro for their potential activity against a cultured Trypanosoma brucei brucei 427 strain. Several compounds displayed mostly modest in vitro anti-trypanosomal activity with compounds 10e and 10h emerging as active candidates with IC50 values of 4.09 and 5.11 μM, respectively. More importantly, a concomitant assessment of their activity against a human cervix adenocarcinoma (HeLa) cell line revealed that these compounds are non-toxic.

Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors

Humans have two glutaminase genes, GLS (GLS1) and GLS2, each of which has two alternative transcripts: the kidney isoform (KGA) and glutaminase C (GAC) for GLS, and the liver isoform (LGA) and glutaminase B (GAB) for GLS2. Initial hit compound (Z)-5-((1-(

Design and development of pyrrole carbaldehyde: An effective pharmacophore for enoyl-ACP reductase

Enoyl-ACP reductase is the key enzyme involved in FAS-II synthesis of mycolic acid in bacterial cell wall and is a promising target for discovering new chemical entity. The designed pharmacophores are the possible better tools to combat mutation in enoyl-ACP enzyme, which leads to a decrease in volume of triclosan binding site. Compound 3a showed H-bonding interactions similar to that of triclosan with enoyl-ACP enzyme and with a better docking score (C score 8.81), while the compound 3f showed additional interaction with MET98.H amino acid residue. The 3D-QSAR computations also support the docking study to develop novel pyrrole-based derivatives. Graphical abstract: Molecular docking 3D-QSAR studies and synthesis of active analogs of pyrrole carbaldehyde as better receptor fit pharmacophore for enoyl-ACP reductase along with in vitro antitubercular activity. (Figure Presented).

Discovery and optimisation studies of antimalarial phenotypic hits

There is an urgent need for the development of new antimalarial compounds. As a result of a phenotypic screen, several compounds with potent activity against the parasite Plasmodium falciparum were identified. Characterization of these compounds is discussed, along with approaches to optimise the physicochemical properties. The in vitro antimalarial activity of these compounds against P. falciparum K1 had EC50 values in the range of 0.09e29 mM, and generally good selectivity (typically >100-fold) compared to a mammalian cell line (L6). One example showed no significant activity against a rodent model of malaria, and more work is needed to optimise these compounds.

Discovery and structure-activity relationships of pyrrolone antimalarials

In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 ～ 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.